[Integrative assessment of the effectiveness and safety of outpatient use of Picamilon].
Andrey DanilovN N ShindryaevaI V BorodulinaT D LunegovPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
The use of Picamilon is effective in patients with stage I CCI, contributes to a significant regression of neurological deficits, cognitive impairment, improved sleep quality and autonomic function; improves vascular endothelial function, reduces the risk of atherosclerosis and cardiovascular complications in patients. The optimal duration of therapy with Picamilon in stage I of chronic cerebral ischemia is 2 months.
Keyphrases
- cerebral ischemia
- sleep quality
- cognitive impairment
- end stage renal disease
- subarachnoid hemorrhage
- blood brain barrier
- chronic kidney disease
- ejection fraction
- newly diagnosed
- brain injury
- cardiovascular disease
- traumatic brain injury
- heart rate variability
- heart rate
- type diabetes
- prognostic factors
- blood pressure
- physical activity
- drug induced